Alex C. Sapir's most recent trade in Fulcrum Therapeutics Inc was a trade of 582,000 Stock option - Right to Buy done . Disclosure was reported to the exchange on Jan. 24, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Fulcrum Therapeutics Inc | Alex C. Sapir | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 582,000 | 582,000 | - | - | Stock option - Right to Buy | |
| Fulcrum Therapeutics Inc | Alex C. Sapir | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jul 2024 | 150,000 | 2,280,400 | - | - | Stock option - Right to Buy | |
| Fulcrum Therapeutics Inc | Alex C. Sapir | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.27 per share. | 03 Jul 2024 | 150,000 | 193,360 (0%) | 0% | 3.3 | 490,500 | Common Stock |
| Fulcrum Therapeutics Inc | Alex C. Sapir | Director, See Remarks | Purchase of securities on an exchange or from another person at price $ 11.35 per share. | 04 Mar 2024 | 43,360 | 43,360 (0%) | 0% | 11.3 | 492,028 | Common Stock |